Treatment outcomes in patients with seropositive versus seronegative rheumatoid arthritis in Phase III randomised clinical trials of tofacitinib

OBJECTIVES: Tofacitinib is an oral JAK inhibitor for the treatment of rheumatoid arthritis (RA). We examined response to tofacitinib 5 or 10 mg two times a day in patients with seropositive vs seronegative RA. METHODS: Data were pooled from five Phase III studies of conventional synthetic disease-mo...

Descripción completa

Detalles Bibliográficos
Autores principales: Bird, Paul, Hall, Stephen, Nash, Peter, Connell, Carol A, Kwok, Kenneth, Witcombe, David, Thirunavukkarasu, Krishan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2019
Materias:
Rheumatoid Arthritis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6397430/
https://www.ncbi.nlm.nih.gov/pubmed/30886732
http://dx.doi.org/10.1136/rmdopen-2018-000742

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6397430/
https://www.ncbi.nlm.nih.gov/pubmed/30886732
http://dx.doi.org/10.1136/rmdopen-2018-000742

Ejemplares similares